ROIVANT SCIENCES LTD. Weighted Average Number of Shares Outstanding, Basic and Diluted
ROIVANT SCIENCES LTD. (ROIV) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 669.75 million shares for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-06-28
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 692.21M shares, a 9.36% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 686.59M shares, a 9.04% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 650.23M shares, a 3.41% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 222.08M shares, a 3.35% increase year-over-year.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for fiscal 2022 was 669.75M shares, a 6.30% increase from fiscal 2021.
- ROIVANT SCIENCES LTD. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 630.05M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 692.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | 689.40M shares derived: average of 2 quarters · filed 2022-06-28 | 676.34M shares derived: average of 3 quarters · filed 2022-06-28 | 669.75M shares 10-K · filed 2022-06-28 |
| 2021-12-31 | 686.59M shares 10-Q · filed 2022-02-14 | 668.41M shares derived: average of 2 quarters · filed 2022-02-14 | 662.27M shares 10-Q · filed 2022-02-14 | 547.96M shares derived: average of 4 quarters · filed 2022-06-28 |
| 2021-09-30 | 650.23M shares 10-Q · filed 2021-11-15 | 650.04M shares 10-Q · filed 2021-11-15 | 501.75M shares derived: average of 3 quarters · filed 2022-06-28 | 533.73M shares derived: average of 4 quarters · filed 2022-06-28 |
| 2021-06-30 | 222.08M shares 10-Q · filed 2021-09-21 | 427.52M shares derived: average of 2 quarters · filed 2022-06-28 | 494.90M shares derived: average of 3 quarters · filed 2022-06-28 | 528.37M shares derived: average of 4 quarters · filed 2022-06-28 |
| 2021-03-31 | 632.96M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | 631.31M shares derived: average of 2 quarters · filed 2022-06-28 | 630.47M shares derived: average of 3 quarters · filed 2022-06-28 | 630.05M shares 10-K · filed 2022-06-28 |
| 2020-12-31 | 629.67M shares 10-Q · filed 2022-02-14 | 629.22M shares derived: average of 2 quarters · filed 2022-02-14 | 629.08M shares 10-Q · filed 2022-02-14 | |
| 2020-09-30 | 628.78M shares 10-Q · filed 2021-11-15 | 628.78M shares 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | 214.88M shares 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |